Patent · US Expired

Determination of responders to chemotherapy

US7655414B2 · kind B2 · utility

2Cited by

6References

9Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Ulrich Brennscheidt · Riehen, CH
Astrid Heller · Penzberg, DE
Verena Lutz · Hersbruck, DE
Joachim Moecks · Mannheim, DE
Carol Ward · Helfrantzkirch, FR

Key dates

Filing date	May 10, 2006
Grant date	Feb 2, 2010
Priority date	—
Expiry date	May 10, 2026

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.